A phase 1/1b clinical trial for patients with KRAS mutant, unresectable, locally advanced and/ metastatic NSCLC, PDAC, and CRC.
About COVALENT-102
This is a multicenter, open-label, non-randomized trial seeking to determine whether BMF-219, either as once daily or twice daily, oral treatment, is safe and effective for patients with patients with KRAS mutations in Non-small cell lung cancer, Pancreatic cancer, and Colorectal cancer.
What is the NCT number for COVALENT-102?
The National Clinical Trial reference number is: NCT05631574
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
What does it mean it is open label, non-randomized?
It means all patients will receive the BMF-219, the study drug and that the dose level will be pre-allocated. There will be no placebo and the allocation will not be based on chance.
Will it cost me anything?
Study medication and study-related care will be provided at no cost.
Patient eligibility
Age:
18 years & over
18 years & over
Sex:
Female & Male
Female & Male
Conditions:
Solid Tumors
Solid Tumors
Patients would qualify for the trial if they meet the following criteria:
- Be 18 years of age or older
- All sexes included
Have either:
- NSCLC and at least 2 but no more than 4 previous treatments, or
- Pancreatic cancer and have received at least one previous treatment, or
- CRC and have received at least one previous treatment
And also:
- Have any type of KRAS mutation in their cancer
- Have not had success with standard of care treatments
- Had cancer come back or get worse after getting better
The science behind COVALENT-102
Menin, a protein involved in transcriptional regulation, impacting cell cycle control, apoptosis, and DNA damage repair, plays a direct role in oncogenic signaling in multiple cancers. Inhibition of menin is a novel approach to cancer treatment.
In preclinical studies, BMF-219 achieves rapid and near complete reduction of target oncogene expression including NPM1, MYC, HOX, MEIS1, BCL2, and KRAS-related tumors.
What is BMF-219?
BMF-219 is an investigational, orally bioavailable small molecule, which covalently binds to the scaffold protein menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Trial locations
Contact us
Phone:
1 (844) 245-0490
1 (844) 245-0490
If you think this clinical trial might be a good fit and you’re interested in taking part, fill out the form below or call our hotline to contact our clinical trials team.